brequinar has been researched along with Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kadir, MFA; Nellore, K; Othman, S | 1 |
| Fang, B; Gan, B; Koppula, P; Lee, H; Lei, G; Liu, X; Mao, C; Olszewski, K; Poyurovsky, MV; Wu, S; Yan, Y; Zhang, Y; Zhuang, L | 1 |
| Peters, GJ | 1 |
| Buzaid, AC; Hait, WN; Marsh, JC; Murren, JR; Pizzorno, G; Poo, WJ; Ravikumar, TS; Strair, RK; Todd, M | 1 |
| Adams, DB; Agra, AM; Bertino, JR; Chi, CL; Currie, VE; King, SY; Pieniaszek, HJ; Quon, CY; Shen, HS | 1 |
| Awada, A; Brentzel, J; Brown, TD; Burris, HA; King, SY; Kuhn, JG; Lynch, W; O'Rourke, TJ; Raymond, E; Von Hoff, DD | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Laurensse, EJ; Nadal, JC; Peters, GJ; Pinedo, HM; Schwartsmann, G; van der Vijgh, WJ; van Groeningen, CJ | 1 |
| Dodion, P; Gall, H; Joggi, J; Schwartsmann, G; Simonetti, G; ten Bokkel Huinink, WW; van der Vijgh, WJ; van Hennik, MB; Vermorken, JB; Winograd, B | 1 |
| Abeloff, MD; Adams, DB; Clarke, BV; Ettinger, DS; Grochow, LB; Hantel, A; McGuire, WB; Noe, DA; Rowinsky, EK; Shen, HS | 1 |
| Armand, JP; Bork, E; Dodion, P; Nieboer, C; Pinedo, HM; Schwartsmann, G; Seldenrijk, CA; ten Bokkel Huinink, WW; Vermorken, JB | 1 |
| Bork, E; Hansen, HH; Vest, S | 1 |
| Crespeigne, N; Dodion, P; Gall, H; Joggi, G; Klein, I; Schwartsmann, G; ten Bokkel Huinink, WW; van der Vijgh, WJ; van Hennik, MB; Vermorken, JB | 1 |
| Arteaga, CL; Beougher, K; Brentzel, HJ; Brown, TD; Kuhn, JG; O'Rourke, TJ; Shen, HS; Von Hoff, DD; Weiss, GR | 1 |
| Boven, E; Fodstad, O; Lobbezoo, MW; Pinedo, HM; Winograd, B | 1 |
2 review(s) available for brequinar and Neoplasms
| Article | Year |
|---|---|
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
6 trial(s) available for brequinar and Neoplasms
| Article | Year |
|---|---|
Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Topics: Aged; Animals; Antineoplastic Agents; Biphenyl Compounds; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Female; Humans; Male; Mice; Middle Aged; Neoplasms; Oxidoreductases Acting on CH-CH Group Donors; Rats; Uridine | 2018 |
Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Uridine | 1995 |
Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.
Topics: Antineoplastic Agents; Biphenyl Compounds; Half-Life; Humans; Injections, Intravenous; Metabolic Clearance Rate; Neoplasms; Protein Binding; Serum Albumin | 1994 |
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cisplatin; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Topics: Aged; Antineoplastic Agents; Biphenyl Compounds; Diarrhea; Drug Administration Schedule; Drug Eruptions; Drug Evaluation; Female; Humans; Male; Middle Aged; Mucous Membrane; Nausea; Neoplasms; Skin Ulcer; Stomatitis; Vomiting | 1989 |
9 other study(ies) available for brequinar and Neoplasms
| Article | Year |
|---|---|
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Topics: Biphenyl Compounds; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dicarboxylic Acids; Dihydroorotate Dehydrogenase; Energy Metabolism; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Oxidoreductases Acting on CH-CH Group Donors | 2020 |
DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Topics: Animals; Biphenyl Compounds; Cell Line, Tumor; Dihydroorotate Dehydrogenase; Female; Ferroptosis; Gene Deletion; Humans; Lipid Peroxidation; Metabolomics; Mice, Nude; Mitochondria; Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Xenograft Model Antitumor Assays | 2021 |
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Dihydroorotate Oxidase; Dose-Response Relationship, Drug; Humans; Lymphocytes; Mice; Mice, Inbred BALB C; Neoplasms; Oxidoreductases; Reference Values; Uridine | 1990 |
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Biphenyl Compounds; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Neoplasms; Platelet Count | 1990 |
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Topics: Antineoplastic Agents; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Evaluation; Female; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1990 |
A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biphenyl Compounds; Drug Administration Schedule; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Platelet Count; Urologic Neoplasms | 1989 |
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Biphenyl Compounds; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms | 1989 |
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Topics: Adult; Aged; Antineoplastic Agents; Biphenyl Compounds; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1989 |
Preclinical phase II studies in human tumor lines: a European multicenter study.
Topics: Amsacrine; Animals; Antineoplastic Agents; Biphenyl Compounds; Cell Line; Doxorubicin; Drug Evaluation; Europe; Humans; International Cooperation; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms | 1988 |